Karragenanın İnsan Meme Kanseri Hücre Hatlarında Sitotoksik Etkisinin İncelenmesi

Abstract

In this thesis stage, the dose and time dependent cytotoxic effects of carrageenan on MCF-7, MDA-MB-231, SKBR-3 breast cancer cell lines and healthy breast epithelial cell line SVCT were investigated. Carregenan is a sulfated polysaccharide molecule of high molecular weight, which is formed from the combination of galactose and anhydrogalactose subunits with glycosidic bonds obtained from seaweeds. Although carrageenans are widely used in the food industry, their use for pharmaceutical and medical purposes has become widespread in recent years. Studies have shown that carregenan also has immunomodulatory, anticoagulant, antithrombotic, antiviral and anti-tumoral effects. Cytotoxicity in cells (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) MTT test; dead and viable cells were determined by acridine orange / propidium iodide (AO / PI) staining. The concentrations determined for application to the cells in the experiment were added to the wells with 200 µl of prepared stock solution and DMEM F-12 media. The cell lines used were prepared as carrageenan concentrations and control groups. Carrageenan was not administered to the control group. Carrageenan MCF-7, MDAMB-231, SKBR-3 breast cancer cell lines and healthy breast epithelial cell line SVCT cells 1000 µg / ml, 250 µg / ml, 62.5µg / ml, 15.62 µg / ml, 3.90 µg / ml and DMEM F- 12 medium were applied to the control group and incubated for 24, 48 and 72 hours. In our results, it has been shown that carrageenan has a cytotoxic effect at high doses, and it has been found that it has a direct effect on apoptotic cell death in these cells. However, it is obvious that in vitro and in vivo studies need to be done on this subject. Based on these results, it can be concluded that carrageenan is a safe, less toxic substance in therapies to prevent cancer formation and progression. It is thought to constitute the first step in the investigation of its usability for breast cancer, which is common in the world and in our country, as an in vitro step. In order to be used clinically, it must be supported by in vivo and in vitro studies.